OCRELIZUMAB

Search structure
Trade Names:
Synonyms:
2H7
Status: Approved (2017)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L04AA36
UNII: A10SJL62JY

Pharmacology

Action Mechanism of Action Reference
BINDING AGENT B-lymphocyte antigen CD20 binding agent PubMed
Primary Target
CD20 (membrane-spanning 4-domains, subfamily A, member 1)

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Multiple Sclerosis, Relapsing-Remitting 4 D020529 FDA
Multiple Sclerosis, Chronic Progressive 4 D020528 FDA
Multiple Sclerosis 4 D009103 ClinicalTrials
Multiple Sclerosis, Chronic Progressive 4 D020528 ClinicalTrials
Lupus Erythematosus, Systemic 3 D008180 ClinicalTrials
Arthritis, Rheumatoid 3 D001172 ClinicalTrials
Encephalitis, Japanese 2 D004672 ClinicalTrials
Lymphoma, Non-Hodgkin 1 D008228 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
14.86
Nervous system disorders
13.11
Infections and infestations
12.87
Respiratory, thoracic and mediastinal disorders
10.82
Skin and subcutaneous tissue disorders
6.8
Gastrointestinal disorders
6.03
Musculoskeletal and connective tissue disorders
5.45
Injury, poisoning and procedural complications
4.27
Psychiatric disorders
3.81
Immune system disorders
3.39
Renal and urinary disorders
3.18
Vascular disorders
3.02
Cardiac disorders
2.99
Investigations
2.89

Cross References

Resources Reference
CAS NUMBER 637334-45-3
ChEMBL CHEMBL2108041
FDA SRS A10SJL62JY
Guide to Pharmacology 7580
CONTENTS